Sanofi said that it has presented the results of a new network meta-analysis of Soliqua, Korea's first fixed ratio co-formulation diabetes treatment, during the International Diabetes Federation (IDF) Conference 2019 in Busan, South Korea.
|Sanofi's diabetes treatment Soliqua|
According to the results, patients with type 2 diabetes had a lower incidence of nausea compared to glucagon-like peptide-1 receptor agonist (GLP-1 RA).
The results showed that Soliqua significantly reduced the incidence of nausea by 52-68 percent compared to GLP-1 RA administered once daily during the first 12 weeks of treatment.
There was no statistically significant decrease in nausea incidence, either, compared to GLP-1 RA administered once weekly.
"Concerns about tolerability and hypoglycemia risk, with or without GLP-1 RA and insulin treatment, are often the reason patients are hesitant to strengthen their diabetes treatment as recommended by global guidelines," said Professor Christopher Rayner at the University of Adelaide and lead author of the study.
The differences in tolerability observed in the study may help address concerns about early treatment enhancement, thus reducing the risk of long-term complications in patients with type 2 diabetes, he added.
Maha Radhakrishnan, Sanofi's global head of primary medical care, also said, "More than two-thirds of people with type 2 diabetes who are taking oral medications are not reaching their recommended global blood sugar levels."
The study continues to show that Soliqua has an efficacy and safety profile that helps patients with type 2 diabetes reach their target blood sugar without adverse events, Radhakrishnan added.
<© Korea Biomedical Review, All rights reserved.>